Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Digestive System Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Lung Neoplasms

Pancreatic Neoplasms

Carcinoma, Renal Cell

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Liver Diseases

Pancreatic Cancer

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Hematinics

All Drugs and Chemicals

Liver Extracts

all patient is observed for SBRT treatment error after fiducial marker implantation.

the fiducial marker was implanted with 3D template assistance under CT guidance

SBRT

Qiu Bin, M.D.

Qiu Bin

This is a clinical study focused on the use of fiducial marker-guided stereotactic body radiotherapy (SBRT) for treating malignant tumors, including lung, liver, pancreatic, and kidney/adrenal cancers. Here's a breakdown of the key components of the study:

Study Design: Prospective, single-center, exploratory clinical study.

Patient Enrollment: The study intends to enroll patients diagnosed with malignant tumors requiring fiducial marker-guided SBRT. Each tumor type (lung, liver, pancreatic, kidney/adrenal) aims to include 15 cases.

Informed Consent: Patients are required to sign informed consent before participating in the study, indicating their understanding of the procedures, risks, and benefits involved.

Intervention: Enrolled patients will undergo stereotactic radiotherapy for their respective malignant tumors. During this process, fiducial markers will be implanted according to the study protocol.

Monitoring: Following implantation of fiducial markers, the study will monitor adverse events associated with the procedure. This includes any complications or side effects resulting from the marker implantation process.

Success Rate: The study will assess the success rate of fiducial marker implantation. This likely involves evaluating the accuracy and reliability of marker placement for guiding SBRT treatment.

SBRT Treatment Error: The study will also monitor SBRT treatment errors. This involves tracking any deviations or inaccuracies in the delivery of stereotactic radiotherapy, potentially caused by issues such as improper fiducial marker placement or technical errors in treatment administration.

Overall, the study aims to explore the feasibility and effectiveness of using fiducial marker-guided SBRT for treating various types of malignant tumors to assess both the safety and the efficacy with a focus on patient outcomes and treatment accuracy.

The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy

Study on the Optimal Number of Fiducial Marker Implanted With 3D-template Assitance for Stereotactic Body Radiotherapy

Error in fiducial marker tracking during each fraction of SBRT

Peking University Third Hospital

Doctor-in-charge

Symptoms and General Pathology

Disease Progression

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

Amino Acids

Docetaxel

Cisplatin

Mitogens

Tyrosine Kinase Inhibitors

Endostar protein

Endostatins

Gefitinib

Angiogenesis Inhibitors

Growth Inhibitors

Tyrosine

Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14

Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo

Recombinant human endostatin

Placebo

Li Liang, MD

Here we are going to find a method by using available multiple drugs including angiogenesis medicine - Endostar to treat lung cancer patients who acquired resistence from EGFR-TKI but have responsed to it before.

Lung cancer patients who received epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI) will acquiring resistance to the drug. This is a study of using Endostar, an angiogentic medicine, combination with chemotherapy and EGFR-TKI in lung cancer rechallenging treatment after resistance of EGFR-TKI and progression disease.

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

A Study of Endostar Combination With Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Rechallenging Treatment After Resistance of EGFR-TKI and Tumor Progression

Associate chief physician

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy	NCT06342323	Lung Cancer Liver Cancer Pancreatic Canc... Renal Cell Carc...	SBRT	18 Years -	Peking University Third Hospital
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy	NCT06342323	Lung Cancer Liver Cancer Pancreatic Canc... Renal Cell Carc...	SBRT	18 Years -	Peking University Third Hospital
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.	NCT02350361	Lung Cancer	Recombinant hum... Placebo	18 Years - 75 Years	Peking University Third Hospital
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy	NCT06342323	Lung Cancer Liver Cancer Pancreatic Canc... Renal Cell Carc...	SBRT	18 Years -	Peking University Third Hospital

Spots Global Cancer Trial Database for lung caner

Every month we try and update this database with for lung caner cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for lung caner

Every month we try and update this database with for lung caner cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for lung caner cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.